The Hunterbrook report claims that Ensign Group’s business model depends on inadequate patient care, with investigators asserting that taxpayer funds were diverted to executives and affiliates. These findings, which surfaced after a five-month investigation, allege that the company's internal practices have led to patient harm and fatalities. The subsequent market reaction wiped significant value from the company's valuation on the NASDAQ exchange.

Rosen Law is now soliciting shareholders who suffered losses to join a prospective class action suit. The firm, led by Laurence Rosen, argues that investors should seek counsel with a proven track record in securities litigation. While the investigation remains ongoing, the law firm emphasizes that shareholders may be eligible for compensation under a contingency fee arrangement, meaning no out-of-pocket costs for participants. Interested parties are directed to the firm’s website or contact Phillip Kim, Esq. for further details regarding the potential recovery of investment losses.